BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, February 1, 2026
Home » Authors » David Ho

Articles by David Ho

An unconventional model: Caywon taking advantage of Crowd Machine platform

Dec. 27, 2017
By David Ho
HONG KONG – Caywon Pharmaceutical Group Ltd. is using Crowd Machine technology to become one of the first companies in China to specialize in decentralizing the pharmaceuticals development process.
Read More

An unconventional model: Caywon taking advantage of Crowd Machine platform

Dec. 22, 2017
By David Ho
HONG KONG – Caywon Pharmaceutical Group Ltd. is using Crowd Machine technology to become one of the first companies in China to specialize in decentralizing the pharmaceuticals development process.
Read More

Transenterix signs $29M deal for surgical robot asset commercialization in China

Dec. 21, 2017
By David Ho

Korea tightens regulations for med-tech industry, eases requirements for biotech

Dec. 20, 2017
By David Ho

Advent Access raises $2M in largest pre-series A financing for SEA med-tech firm

Dec. 14, 2017
By David Ho

Sanofi's Dengvaxia faces legal threat, investigations after Philippines suspension

Dec. 13, 2017
By David Ho
HONG KONG – Controversy has continued to mount in the Philippines around Sanofi Pasteur Ltd.'s dengue vaccine, Dengvaxia, which is now facing questions about its effectiveness and the manner and speed with which the government adopted it in its national vaccination program.
Read More

Sanofi's Dengvaxia faces legal threat, investigations after Philippines suspension

Dec. 13, 2017
By David Ho
HONG KONG – Controversy has continued to mount in the Philippines around Sanofi Pasteur Ltd.'s dengue vaccine, Dengvaxia, which is now facing questions about its effectiveness and the manner and speed with which the government adopted it in its national vaccination program.
Read More

Singapore's Kronikare developing AI system for chronic wound assessment

Dec. 11, 2017
By David Ho

GE Healthcare signs deal to develop first-in-market tech for ultrasound devices

Dec. 6, 2017
By David Ho

Astrazeneca, Chinese Future Industry Investment Fund launch JV for novel drugs

Dec. 6, 2017
By David Ho
HONG KONG – Astrazeneca plc has teamed up with the Chinese Future Industry Investment Fund (FIIF) to form a joint venture in China for drug development via an equally owned, stand-alone company named Dizal Pharmaceutical.
Read More
Previous 1 2 … 56 57 58 59 60 61 62 63 64 … 71 72 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing